Harvard Bioscience (HBIO) EPS (Basic) (2010 - 2026)

Harvard Bioscience (HBIO) has 16 years of EPS (Basic) data on file, last reported at -$0.77 in Q1 2026.

• On a quarterly basis, EPS (Basic) rose 93.29% year-over-year to -$0.77 in Q1 2026; TTM through Mar 2026 was -$2.18, a 83.32% increase from a year earlier, with the FY2025 full-year figure at -$12.77, down 359.78% from the prior year.
• EPS (Basic) for Q1 2026 stood at -$0.77, down from -$0.63 in the prior quarter.
• Over the last five years, EPS (Basic) for HBIO reached as high as $0.59 in Q2 2022 and fell as low as -$11.41 in Q1 2025.
• Historically, EPS (Basic) has averaged -$1.13 across 5 years, with a median of -$0.52 in 2025.
• On a YoY basis, EPS (Basic) climbed as much as 647.94% in 2022 and fell as far as 1860.46% in 2022.
• Year by year, EPS (Basic) stood at -$0.4 in 2022, then soared by 72.69% to -$0.11 in 2023, then soared by 175.27% to $0.08 in 2024, then slumped by 867.74% to -$0.63 in 2025, then fell by 20.58% to -$0.77 in 2026.
• Per Business Quant data, the three most recent EPS (Basic) figures were -$0.77 in Q1 2026, -$0.63 in Q4 2025, and -$0.28 in Q3 2025.